THE NEWS: India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable.
THE NUMBERS: Bayer Corp. markets sorefinib as Nexavar for about $5,600 a month in India under a 2008-2020 patent, while Natco Pharma Ltd. said its version would cost Indian patients $175 a month.
THE BACKGROUND: It was the first case of compulsory licensing under India's patent laws passed in 2005. Under the license Natco must pay 6 percent in royalties to Bayer.
Source: http://news.yahoo.com/summary-box-india-licenses-bayer-cancer-drug-162659713.html
huntingtons disease rob the firm new york philharmonic marines urinating on taliban critics choice awards super pac
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.